Summary & Overview
CPT 67221: Ophthalmic Laser-Activated Intraocular Tumor Therapy
CPT code 67221 identifies a specialized ophthalmic interventional procedure in which a provider infuses a photosensitive drug into the eye to treat a localized cancerous focus in the middle layer (uveal tract) and activates the agent using a laser. The code captures a targeted, eye-preserving treatment option for intraocular neoplasms and is relevant for ophthalmologists, oncology teams, and payers managing high-acuity ocular oncology services. Nationally, the procedure is significant because it represents a modality that can reduce the need for more invasive surgery and can impact utilization patterns in ambulatory surgical centers and hospital outpatient departments.
This publication covers coverage and reimbursement context for major payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find: benchmark descriptions of typical sites of service and service type; an explanation of clinical context and procedural intent; and a concise guide to where to find additional coding, billing, and coverage resources. Data not available in the input is noted where applicable. The piece is intended to inform clinical billing staff, coding professionals, and policy analysts about the clinical scope of CPT code 67221, payer relevance, and practical considerations for billing and site-of-service classification.
Billing Code Overview
CPT code 67221 describes a targeted ophthalmologic procedure in which a provider treats a localized cancerous focus within the middle layer of one eye by infusing a photosensitive drug that is activated by application of a laser beam. This procedure is a form of localized intravitreal or intraocular drug infusion with subsequent laser activation to ablate or control a neoplastic lesion in the eye.
-
Service type: Interventional ophthalmic tumor therapy using intraocular drug infusion with laser activation
-
Typical site of service: Ambulatory surgery center or hospital outpatient department specializing in ophthalmic procedures
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a small, localized choroidal melanoma or other ocular malignancy confined to the mid-choroidal layer of one eye. The patient often presents with decreased vision, visual field defect, photopsias, or a visible choroidal mass on ophthalmic exam. Diagnostic workup includes dilated fundus examination, fundus photography, ocular ultrasound (A-scan/B-scan), optical coherence tomography, and fluorescein or indocyanine green angiography as indicated. A multidisciplinary team—comprising an ophthalmic oncologist, ocular surgeon, radiation oncologist, and anesthesiology—evaluates tumor size, location, and proximity to critical structures (macula, optic nerve).
The procedure described by 67221 is a targeted intraocular chemotherapy (photodynamic or other light-activated drug infusion) where a photosensitizing agent is delivered to treat a localized cancerous focus in the mid-layer of one eye and activated by a laser. Typical workflow: preoperative informed consent and clearance, perioperative sedation or general anesthesia depending on patient and tumor factors, sterile ocular preparation, localized infusion or intravitreal/intraocular administration of the photosensitizer, precise laser activation to the lesion under microscopic or indirect visualization, monitoring for immediate complications, and postoperative observation. Postoperative care includes topical antibiotics and steroids as indicated, scheduled ophthalmic follow-up with imaging to assess tumor response, and coordination with oncology for adjuvant therapy if needed.
Typical site of service is an ambulatory surgical center or hospital operating room with ophthalmic surgical capability. The service type is a specialized ophthalmic operative procedure: intraocular, tumor-directed infusion with photochemical activation.
Coding Specifications
| Modifier | Description |
|---|